| scholarly article | Q13442814 |
| P2093 | author name string | Angelika Banzhoff | |
| P2860 | cites work | Prospects for vaccine prevention of meningococcal infection | Q24537338 |
| NadA, a novel vaccine candidate of Neisseria meningitidis | Q24675323 | ||
| Meningococcal B vaccine and the vision of a meningitis free world | Q26770696 | ||
| Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults | Q26799455 | ||
| Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates | Q27653843 | ||
| MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine | Q28081147 | ||
| Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction | Q28273949 | ||
| Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme | Q28391723 | ||
| Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data | Q30841372 | ||
| The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology | Q33610843 | ||
| Epidemiological profile of meningococcal disease in the United States | Q33648635 | ||
| Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans | Q33734798 | ||
| Meningococcal carriage by age: a systematic review and meta-analysis | Q33746085 | ||
| Meningococcal disease | Q34239234 | ||
| Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study | Q34316082 | ||
| The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. | Q34601395 | ||
| Social behavior and meningococcal carriage in British teenagers | Q36026157 | ||
| First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak | Q36206141 | ||
| Human immunity to the meningococcus. I. The role of humoral antibodies | Q36269707 | ||
| The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance | Q36470692 | ||
| The changing epidemiology of meningococcal disease in North America 1945-2010. | Q36887966 | ||
| A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program | Q37471668 | ||
| Vaccine adherence in adolescents | Q37502469 | ||
| Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future | Q37514748 | ||
| The changing and dynamic epidemiology of meningococcal disease | Q37969481 | ||
| Meningococcal disease: clinical presentation and sequelae. | Q38011313 | ||
| IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. | Q38298601 | ||
| Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. | Q38525922 | ||
| Vaccines for prevention of group B meningococcal disease: Not your father's vaccines | Q38538836 | ||
| Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years | Q38591053 | ||
| Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. | Q38674381 | ||
| Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial | Q39387871 | ||
| Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany | Q39826439 | ||
| Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France | Q39899128 | ||
| Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus | Q39981028 | ||
| Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. | Q40402876 | ||
| Global epidemiology of meningococcal disease and vaccine efficacy. | Q40461282 | ||
| Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. | Q40468661 | ||
| Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College - Rhode Island, 2015. | Q40842298 | ||
| Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. | Q41077558 | ||
| A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. | Q41400370 | ||
| The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. | Q42204205 | ||
| Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States | Q42266218 | ||
| Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q42270134 | ||
| National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2013 | Q43959507 | ||
| Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. | Q44735039 | ||
| Risk factors for meningococcal disease in college students | Q44937042 | ||
| Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study | Q56706209 | ||
| Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study | Q57540116 | ||
| Risk Factors for Meningococcal Disease in Students in Grades 9–12 | Q59230685 | ||
| Clinical recognition of meningococcal disease in children and adolescents | Q82470641 | ||
| Meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness | Q87513376 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3-14 | |
| P577 | publication date | 2017-01-06 | |
| P1433 | published in | Therapeutic advances in vaccines | Q26842222 |
| P1476 | title | Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States | |
| P478 | volume | 5 |
| Q92743253 | A physician's guide to the 2-dose schedule of MenB-FHbp vaccine |
| Q91257609 | Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine |
| Q64132145 | Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide |
| Q90043871 | Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine |
| Q92968763 | Meningococcal pneumonia: a review |
| Q92151909 | The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study |
| Q54964676 | Vaccination strategies for the prevention of meningococcal disease. |
Search more.